Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laurie B Grossberg

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Gastroenterology|November 5, 2016
A National Survey of the Prevalence and Impact of Cytomegalovirus Infection Among Hospitalized Patients With Ulcerative ColitisLaurie B Grossberg, Ghideon Ezaz, Douglas Grunwald, et al.
Inflammatory Bowel Diseases|December 23, 2017
A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel DiseaseLaurie B Grossberg, Konstantinos Papamichael, Joseph D Feuerstein, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases|September 26, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel DiseaseRachel Porth, Tina Deyhim, Grace Geeganage, et al.
Inflammatory Bowel Diseases|August 26, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with RisankizumabGrace Geeganage, Ajay Gade, Alessandra Saraga, et al.
Digestive Diseases and Sciences|December 9, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with AdalimumabAjay Gade, Alessandra Saraga, Tina Deyhim, et al.
Igie : Innovation, Investigation and Insights|July 3, 2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitmentLaurie B Grossberg, Grace Geeganage, Aditya Mithal, et al.
European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.
Journal of Clinical Medicine|January 28, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel DiseaseAlessandra Saraga, Tina Deyhim, Ajay Gade, et al.
Ebiomedicine|May 29, 2026
Serum proteomics in paediatric inflammatory bowel disease from a case-control study: biomarker discovery and ulcerative colitis-Crohn's disease differentiationMmeyeneabasi Omede, Hasan H Otu, Laurie B Grossberg, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Gastroenterology|November 5, 2016
A National Survey of the Prevalence and Impact of Cytomegalovirus Infection Among Hospitalized Patients With Ulcerative ColitisLaurie B Grossberg, Ghideon Ezaz, Douglas Grunwald, et al.
Inflammatory Bowel Diseases|December 23, 2017
A Survey Study of Gastroenterologists' Attitudes and Barriers Toward Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel DiseaseLaurie B Grossberg, Konstantinos Papamichael, Joseph D Feuerstein, et al.
Inflammatory Bowel Diseases|July 2, 2024
Proactive Therapeutic Drug Monitoring Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel Disease Treated With Intravenous VedolizumabRachel Porth, Tina Deyhim, Samantha Zullow, et al.
Inflammatory Bowel Diseases|September 26, 2024
Proactive Therapeutic Drug Monitoring of Ustekinumab Is Associated With Increased Drug Persistence in Patients With Inflammatory Bowel DiseaseRachel Porth, Tina Deyhim, Grace Geeganage, et al.
Inflammatory Bowel Diseases|August 26, 2025
Long-term Outcomes of Patients with Crohn's Disease Treated with RisankizumabGrace Geeganage, Ajay Gade, Alessandra Saraga, et al.
Digestive Diseases and Sciences|December 9, 2025
Proactive Compared to Reactive Therapeutic Drug Monitoring Is Associated with Less Treatment Failure in Patients with Inflammatory Bowel Disease Treated with AdalimumabAjay Gade, Alessandra Saraga, Tina Deyhim, et al.
Igie : Innovation, Investigation and Insights|July 3, 2026
Artificial intelligence detection of endoscopic moderate-to-severe ulcerative colitis: a novel tool to enhance clinical trial recruitmentLaurie B Grossberg, Grace Geeganage, Aditya Mithal, et al.
European Journal of Gastroenterology & Hepatology|March 23, 2026
Lower drug clearance of adalimumab is associated with proactive therapeutic drug monitoring and mucosal healing in patients with inflammatory bowel diseaseTina Deyhim, Alessandra Saraga, Ajay Gade, et al.
Journal of Clinical Medicine|January 28, 2026
Higher Anti-Drug Antibody Levels to Anti-Tumor Necrosis Factor Therapies Are Associated with Treatment Failure in Patients with Inflammatory Bowel DiseaseAlessandra Saraga, Tina Deyhim, Ajay Gade, et al.
Ebiomedicine|May 29, 2026
Serum proteomics in paediatric inflammatory bowel disease from a case-control study: biomarker discovery and ulcerative colitis-Crohn's disease differentiationMmeyeneabasi Omede, Hasan H Otu, Laurie B Grossberg, et al.
Pageof 3